Not all sufferers with CLL demand therapy. Despite all latest advancements, the iwCLL continue to endorses watchful observation for individuals with asymptomatic disorder.86 This recommendation is based on at the least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR). Anda pasti harus memikirkan https://hansy087eoy8.prublogger.com/profile